Anavex Life Sciences received a Nasdaq delinquency notification for late filing its Form 10-Q, with compliance due by July 20, 2026.
Quiver AI Summary
Anavex Life Sciences Corp. announced on May 20, 2026, that it received a delinquency notification from Nasdaq due to its failure to timely file its Form 10-Q for the quarter ending March 31, 2026. The notification indicates non-compliance with Nasdaq Listing Rule 5250(c)(1), giving the company until July 20, 2026, to submit a plan to regain compliance. Anavex is actively working to complete the necessary filing and comply with the rule, although the notification does not currently affect its common stock trading on Nasdaq. The press release includes forward-looking statements about the company’s intentions regarding compliance and warns of risks and uncertainties associated with these statements.
Potential Positives
- The company has until July 20, 2026, to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1), indicating it has a timeline and an opportunity to address the issue.
- The notification has no immediate effect on the Company’s common stock listed on Nasdaq, allowing it to continue operating without immediate trading repercussions.
- Anavex is actively working to complete and file its Form 10-Q, demonstrating a proactive approach to resolving compliance issues.
Potential Negatives
- The company is at risk of being delisted from Nasdaq due to non-compliance with listing rules after failing to submit its Form 10-Q on time.
- The delinquency notification reflects negatively on the company's operational and management capabilities, which may raise concerns among investors.
- Failure to regain compliance by the July 20, 2026 deadline could negatively impact investor confidence and the company's stock value.
FAQ
What is the recent Nasdaq notice received by Anavex Life Sciences?
Anavex received a delinquency notification for not timely filing its Form 10-Q for the quarter ended March 31, 2026.
What is the deadline for Anavex to regain compliance with Nasdaq?
Anavex has until July 20, 2026, to submit a plan to regain compliance with the Nasdaq Listing Rule.
Will the Nasdaq notice affect Anavex's common stock?
The notification from Nasdaq has no immediate effect on Anavex's common stock listed on the exchange.
What is Anavex Life Sciences Corp. focused on?
Anavex is a biopharmaceutical company dedicated to developing treatments for CNS disorders, including neurodegenerative and neuropsychiatric conditions.
Who can I contact for investor relations at Anavex?
You can contact Alex Arzeno or Tripp Sullivan at SCR Partners for investor relations inquiries regarding Anavex.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVXL Hedge Fund Activity
We have seen 114 institutional investors add shares of $AVXL stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP added 1,594,192 shares (+96.4%) to their portfolio in Q1 2026, for an estimated $4,894,169
- NWAM LLC removed 870,796 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,673,343
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 742,077 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $2,278,176
- HRT FINANCIAL LP added 657,877 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,019,682
- AQR CAPITAL MANAGEMENT LLC added 606,977 shares (+405.2%) to their portfolio in Q1 2026, for an estimated $1,863,419
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 556,164 shares (+126.5%) to their portfolio in Q1 2026, for an estimated $1,707,423
- TWO SIGMA ADVISERS, LP added 451,070 shares (+59.5%) to their portfolio in Q4 2025, for an estimated $1,605,809
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AVXL Analyst Ratings
Wall Street analysts have issued reports on $AVXL in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 01/06/2026
- HC Wainwright & Co. issued a "Buy" rating on 12/19/2025
To track analyst ratings and price targets for $AVXL, check out Quiver Quantitative's $AVXL forecast page.
$AVXL Price Targets
Multiple analysts have issued price targets for $AVXL recently. We have seen 2 analysts offer price targets for $AVXL in the last 6 months, with a median target of $22.0.
Here are some recent targets:
- Jason Kolbert from D. Boral Capital set a target price of $24.0 on 03/31/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $20.0 on 02/10/2026
Full Release
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026. The Notice indicates that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Nasdaq Listing Rule”) as a result of the Company’s inability to timely file its Form 10-Q for the quarterly period ended March 31, 2026.
As indicated in the Notice, the Company has until July 20, 2026, to submit a plan to regain compliance. The Company is working prudently to complete and file the Form 10-Q and submit a plan to regain compliance with the Nasdaq Listing Rule.
This notification has no immediate effect on the Company’s common stock listed on Nasdaq.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Further information is available at www.anavex.com .
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s plans to complete and file its Form 10-Q and to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1). These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s ability to file the Form 10-Q and the Company’s ability to regain compliance with Nasdaq Listing Rule 5250(c)(1) and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent filings and furnishings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.
Investor Relations & Media Contact:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email:
[email protected]
Tripp Sullivan
Tel: 615-942-7077
Email:
[email protected]
Company Contact:
Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email:
[email protected]
